Advertisement
U.S. markets closed
  • S&P 500

    5,254.35
    +5.86 (+0.11%)
     
  • Dow 30

    39,807.37
    +47.29 (+0.12%)
     
  • Nasdaq

    16,379.46
    -20.06 (-0.12%)
     
  • Russell 2000

    2,124.55
    +10.20 (+0.48%)
     
  • Crude Oil

    83.11
    -0.06 (-0.07%)
     
  • Gold

    2,254.80
    +16.40 (+0.73%)
     
  • Silver

    25.10
    +0.18 (+0.74%)
     
  • EUR/USD

    1.0793
    0.0000 (-0.00%)
     
  • 10-Yr Bond

    4.2060
    +0.0100 (+0.24%)
     
  • GBP/USD

    1.2614
    -0.0008 (-0.06%)
     
  • USD/JPY

    151.3300
    -0.0420 (-0.03%)
     
  • Bitcoin USD

    70,222.02
    -524.43 (-0.74%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,952.62
    +20.64 (+0.26%)
     
  • Nikkei 225

    40,369.44
    +201.37 (+0.50%)
     

Takeda Guilty Of Supply Contract Breach With AbbVie For Prostate Cancer Drug

  • In a spat between Takeda Pharmaceutical Co Ltd (NYSE: TAK) and AbbVie Inc (NYSE: ABBV) for Lupron (leuprorelin), a Delaware judge has issued a ruling in favor of AbbVie.

  • The new ruling found that Takeda is guilty of breach of contract for failing to supply its partner with the prostate cancer drug.

  • AbbVie claims that Takeda is responsible for supply chain problems that have led to worldwide shortages.

  • Takeda did not supply AbbVie with enough inventory to fulfill orders from April 2020 until at least March 2021. 106 lots of Lupron had been ordered, with only 41 delivered.

  • AbbVie developed the medicine and distributed it in the U.S and Canada, while Takeda is the drug's sole manufacturer.

  • Glasscock ruled that Takeda failed to maintain the plant in compliance with good manufacturing practices and maintain a safe stock of the drug.

  • Lupron has been in short supply worldwide since 2019 when the company and the FDA discovered "protocol violations" at the plant.

  • Price Action: TAK stock is down 1.46% at $16.90, while ABBV stock is down 0.71% at $106.60 during the market session on the last check Friday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Advertisement